> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Period Set for Pfizer’s Apoquel
- URL: https://www.fdaweb.com/review-period-set-for-pfizers-apoquel/
- Published: 2016-04-12T12:00:00.000Z
- Updated: 2026-09-14T20:54:11.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135338

*Federal Register* Notice: FDA has determined the regulatory review period for Pfizer’s Apoquel (oclacitinib) for extending a patent which claims the animal drug product. Apoquel is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-04-12/pdf/2016-08333.pdf?ref=fdaweb.com)